Phaseline

Companies › Beijing Biotech

Beijing Biotech: clinical trials, targets and expected readouts

27 active drug programs in 41 registered trials: 40 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EB-DART-NK01
Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2)
DLL3, CD56, GD2Phase 1Small Cell Lung Cancer (SCLC)Feb 2027
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1
MSLN, MUC1Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Feb 2027
EB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
EB-NK-MF CAR-NK cells
Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit
MSLN, FOLR1, MUC16, TROP2Phase 1Advanced Solid Tumors; Epithelial Ovarian CancerFeb 2027
Autologous BCMA/CD19 dual-target CAR-T module–Phase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaMar 2027
Autologous BCMA/CD38 dual-target CAR-T module–Phase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaMar 2027
Autologous CD19/CD20 dual-target CAR-T module–Phase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaMar 2027
Autologous CD19/CD22 dual-target CAR-T module–Phase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaMar 2027
Autologous anti-BCMA CAR-T cells
CAR-T cell therapy targeting BCMA-expressing plasma cells
TNFRSF17Phase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSMar 2027
Autologous anti-CD19 CAR-T cells
CAR-T cell therapy targeting CD19-expressing B cells
CD19Phase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Scleroderma, SystemicMar 2027
EB-DT-CAR-NK
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18, ERBB2Phase 1Advanced Gastric AdenocarcinomaMar 2027
EB-DTNB-NK
Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch
GYPC, CD276Phase 1Relapsed NeuroblastomaMar 2027
EB-DUALNK
Dual-target CAR-NK cells (antigen pair to be selected from GD2, MUC1, PSMA, mesothelin)
–Phase 1Epithelial Ovarian CancerMar 2027
EB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
EB-HC01 dual-target CAR-NK cells
Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5
ERBB2, CEACAM5Phase 1CholangiocarcinomaMar 2027
EB-MF-CAR-NK-01
Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro
MSLN, FAPPhase 1Malignant Pleural MesotheliomasMar 2027
EB-PT-CAR-NK-S
Single-target CAR-NK cell therapy
–Phase 1Advanced or Metastatic Solid TumorsMar 2027
EBNK-1822H2
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18A2, ERBB2Phase 1Recurrent or Metastatic Esophageal AdenocarcinomaMar 2027
EGFR/HER2 Dual-Target CAR-NK Cells
Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re
EGFR, ERBB2Phase 1Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMar 2027
ETB-DualNK-01
Dual-target anti-PSMA/PSCA CAR-NK cells
PSMA, PSCAPhase 1Metastatic Castration-resistant Prostate CancerMar 2027
Autologous dual-target CAR-T cells
Patient-derived T cells engineered to recognize two tumor-associated antigens selected fro
–Phase 1Advanced UnresectableApr 2027
EB-701/CA9-NK
Dual-target CD70/CAIX CAR-NK cells
CD70, CA9Phase 1Advanced or Metastatic Clear Cell Renal Cell CarcinomaApr 2027
EB-CAR30-NK
CD30-targeted allogeneic CAR-NK cells
CD30Phase 1B2 ThymomaJun 2027
EB-CAR5-NK
CD5-targeted allogeneic CAR-NK cells
CD5Phase 1B2 ThymomaJun 2027
EB-CARMSLN-NK
Mesothelin-targeted allogeneic CAR-NK cells
MSLNPhase 1B2 ThymomaJun 2027
EB-DT-NK-UC101
Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch
NECTIN4, ERBB2Phase 1Bladder CancerJun 2027
EB-DTKN-401
Dual-target CSPG4/GD2 CAR-NK cells
CSPG4, GD2Phase 1Unresectable MelanomaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07589530EB-NK-MF CAR-NK cellsPhase 1Advanced Solid TumorsOncologyFeb 2027
NCT07480928EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)OncologyFeb 2027
NCT07480928EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)OncologyFeb 2027
NCT07467863EB-G3B7-NK dual-target CAR-NK cellsPhase 1Non-Small Cell Lung CancerOncologyFeb 2027
NCT07486089EB-G3B7-NK dual-target CAR-NK cellsPhase 1Breast Cancer (Locally Advanced or Metastatic)OncologyFeb 2027
NCT07744256EB-DART-NK01Phase 1Small Cell Lung Cancer (SCLC)OncologyFeb 2027
NCT07480213EB-DART-NK01Phase 1Small Cell Lung Cancer (SCLC)OncologyFeb 2027
NCT07480954EB-NK-MF CAR-NK cellsPhase 1Epithelial Ovarian CancerOncologyFeb 2027
NCT07480941EB-G3B7-NK dual-target CAR-NK cellsPhase 1GlioblastomaOncologyFeb 2027
NCT07551362EB-DT-CAR-NKPhase 1Advanced Gastric AdenocarcinomaOncologyMar 2027
NCT07510828EB-PT-CAR-NK-SPhase 1Advanced or Metastatic Solid TumorsOncologyMar 2027
NCT07523555Autologous CD19/CD22 dual-target CAR-T modulePhase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaOncologyMar 2027
NCT07523555Autologous CD19/CD20 dual-target CAR-T modulePhase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaOncologyMar 2027
NCT07523555Autologous BCMA/CD19 dual-target CAR-T modulePhase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaOncologyMar 2027
NCT07523555Autologous BCMA/CD38 dual-target CAR-T modulePhase 1Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaOncologyMar 2027
NCT07589517EB-DUO-CAR-NK-CEA/GCCPhase 1Colorectal CancerOncologyMar 2027
NCT07510815EB-MF-CAR-NK-01Phase 1Malignant Pleural MesotheliomasOncologyMar 2027
NCT07500220EB-G3B7-NK dual-target CAR-NK cellsPhase 1Advanced Hepatocellular Carcinoma (HCC)OncologyMar 2027
NCT07641023EB-G3B7-NK dual-target CAR-NK cellsPhase 1Non-Small Cell Lung CancerOncologyMar 2027
NCT07510802EB-G3B7-NK dual-target CAR-NK cellsPhase 1Breast Cancer (Advanced/Metastatic)OncologyMar 2027
NCT07589543EB-DUALNKPhase 1Epithelial Ovarian CancerOncologyMar 2027
NCT07502287EB-DTNB-NKPhase 1Relapsed NeuroblastomaOncologyMar 2027
NCT07617805EGFR/HER2 Dual-Target CAR-NK CellsPhase 1Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaOncologyMar 2027
NCT07641049ETB-DualNK-01Phase 1Metastatic Castration-resistant Prostate CancerOncologyMar 2027
NCT07523542Autologous anti-CD19 CAR-T cellsPhase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSImmunologyMar 2027
NCT07523542Autologous anti-BCMA CAR-T cellsPhase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSImmunologyMar 2027
NCT07641036EB-HC01 dual-target CAR-NK cellsPhase 1CholangiocarcinomaOncologyMar 2027
NCT07622940EBNK-1822H2Phase 1Recurrent or Metastatic Esophageal AdenocarcinomaOncologyMar 2027
NCT07551349EB-701/CA9-NKPhase 1Advanced or Metastatic Clear Cell Renal Cell CarcinomaOncologyApr 2027
NCT07627711EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)OncologyApr 2027
NCT07627711EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)OncologyApr 2027
NCT07551336EB-G3B7-NK dual-target CAR-NK cellsPhase 1Malignant GliomaOncologyApr 2027
NCT07523529Autologous dual-target CAR-T cellsPhase 1Advanced UnresectableOncologyApr 2027
NCT07617753EB-NK-MF CAR-NK cellsPhase 1Epithelial Ovarian CancerOncologyJun 2027
NCT07627698EB-DTKN-401Phase 1Unresectable MelanomaOncologyJun 2027
NCT07492628EB-DT-NK-UC101Phase 1Bladder CancerOncologyJun 2027
NCT07598955EB-CAR30-NKPhase 1B2 ThymomaOncologyJun 2027
NCT07598955EB-CAR5-NKPhase 1B2 ThymomaOncologyJun 2027
NCT07598955EB-CARMSLN-NKPhase 1B2 ThymomaOncologyJun 2027
NCT07462650EB-DUO-CAR-NK-CEA/GCCPhase 1Colorectal Cancer MetastaticOncologyDec 2027
NCT07493395Autologous anti-CD19 CAR-T cellsPhase 2Scleroderma, SystemicImmunologyJun 2028

Targets

ERBB2 (7) MSLN (5) GD2 (2) CEACAM5 (2) CD276 (2) EGFR (2) CLDN18 (1) CD70 (1) CA9 (1) FOLR1 (1) MUC16 (1) TROP2 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Roche Pfizer Chia Tai Tianqing Pharmaceutical Group Yuhan Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical A2 Biotherapeutics Sichuan Baili Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.